Table 1.
Adjuvants used throughout the course of the study.
| Adjuvant | Type | Formulation | Development Status |
|---|---|---|---|
| Adju-Phos® | Aluminium Phosphate | 1.5mg/ml – rotated for 30 min at 4°C |
Licensed |
| Alhydrogel® | Aluminium Hydroxide | 1.5mg/ml – rotated for 30 min at 4°C |
Licensed |
| Abisco®100 | Phospholipid, cholesterol and saponin complex. Contains a mixture of Matrix A (QS7) and C (contains QS21) fractions which are purified from Quil A extracts |
12μg/dose – mix by shaking |
Clinical development |
| CoVaccine HT™ | Sucrose fatty acid sulphate esters (SFASE) immobilised on the oil droplets of a submicron emulsion of squalane in water |
1:1 – gently mixed | Clinical development |
| EM01 | Stable oil in water emulsion (SE) | 20μg agonist/dose – vortex for 30 s |
Pre-clinical/research stage |
| EM05 | SE + TLR 4 (GLA) | 20μg agonist/dose – vortex for 30 s |
Clinical development |
| EM012 | SE + TLR4/7/8 (GLA &Iziquimod) | 20μg agonist/dose – vortex for 30 s |
Pre-clinical/research stage |
| EM014 | SE + TLR 4/9 (GLA & CpG ODN 1826) |
20μg agonist/dose – vortex for 30 s |
Pre-clinical/research stage |
| EM020 | SE + TLR 4/7/8/9 (GLA & Iziqumod &CpG ODN 1826) |
20μg agonist/dose – vortex for 30 s |
Pre-clinical/research stage |
| Freund’s adjuvant |
Non-metabolisable oils, Complete Freund’s adjuvant contains mycobacterial derivatives |
1:1 – vortex thoroughly | Experimental |
| Montanide ® ISA720 |
Squalene and refined emulsifier/surfactant based on mannide oleate |
3 Ag:7 ISA - emulsified 6 min on ice using a T10 ULTRA-TURRAX® (IKA®) at 25,000rpm |
Clinical development |